This phase II trial is trying to determine whether it is safer and more effective to use an oral targeted therapy alone or as a combination treatment for myelofibrosis.
This trial is treating patients with myelofibrosis.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)
Eligible patients will either receive oral navitoclax alone, once daily (QD) at various doses, or in combination with ruxolitinib at a dose greater than or equal to 10 mg twice daily (BID).
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More